Transforming growth factor beta (TGF-β)
Transforming growth factor beta (TGF-β) is a secreted signaling protein — a multifunctional cytokine that exists in mammals as three closely related isoforms (TGF-β1, TGF-β2, TGF-β3).
Transforming growth factor beta (TGF-β) is a secreted signaling protein — a multifunctional cytokine that exists in mammals as three closely related isoforms (TGF-β1, TGF-β2, TGF-β3). It is synthesized as a latent complex that must be activated before it can bind its receptors; release of the mature ligand from this latent form is a key regulatory step, mediated in part by integrins such as αvβ6, which is induced on epithelial cells during chronic tissue injury. Active TGF-β binds type II and type I serine/threonine kinase receptors, and the activated type I receptor phosphorylates receptor-regulated Smad proteins, which complex with Smad4 and accumulate in the nucleus to control transcription. Non-canonical branches, including MAPK signaling, operate alongside this canonical Smad route.
Biologically, TGF-β governs cell proliferation, differentiation, extracellular matrix deposition, immune regulation, and wound repair, and its effects are strongly context-dependent. In fibrosis, TGF-β/Smad signaling drives activation of stellate and other mesenchymal cells, collagen production, and epithelial-mesenchymal transition — processes central to liver fibrosis in metabolic dysfunction-associated steatohepatitis, intestinal fibrosis in chronic colitis, myocardial and renal fibrosis, and airway scarring; Sirt1-linked metabolic regulation has been implicated upstream of this axis. In cancer, TGF-β acts both as a tumor suppressor in early epithelial lesions and as a driver of invasion, metastasis, and immune evasion in established tumors, where it remodels the tumor microenvironment, promotes regulatory T cell differentiation, and suppresses the cytotoxic function of natural killer cells and CD8+ T cells, contributing to resistance to checkpoint inhibitors such as anti-Programmed cell death 1 (PD-1) and anti-PD-L1 agents. This dual biology makes TGF-β both a mechanistic readout of fibrotic and immunosuppressive disease states and an active therapeutic target: strategies span small-molecule ATP-competitive inhibitors of the type I receptor kinase, ligand- and integrin-directed blockade, targeted protein degradation of pathway components, and cell-engineering approaches that render adoptively transferred immune cells insensitive to TGF-β-mediated suppression.
Where the papers sit
15 papers from the last 6 months study Transforming growth factor beta (TGF-β) directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 observational · 7 preclinical · 7 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Tissue Repair and Inflammation
TGF-β-linked immune activation, fibroblast expansion and tissue remodeling recur across intestinal, cardiac, vascular and wound settings. AMPK–CD103+ dendritic-cell control of Tregs and CARM1-mediated suppression of cross-presentation extend the immune-regulatory theme. Cardiac and intestinal studies target SPHK2/S1P/SMAD3 or TGF-β/Smad signaling to limit fibrosis, while hydrogels and small molecules support repair. The set has no single therapeutic direction, and its kinase-degrader discussion sits apart from the organ-specific studies.
8 papers · 53.3%
-
Cellular Plasticity and Immune Resistance
TGF-β-driven cellular plasticity is being linked to immune exclusion, treatment resistance and heterogeneous tumor responses. CAF–endothelial programs and hypoxia can form barriers associated with checkpoint-inhibitor resistance, while TGF-β1-imprinted CAR-NK cells and IL1RAP targeting pursue ways around the suppressive niche. Single-cell response modeling is shifting analysis toward mechanism-guided patient or cell-state stratification. MiR-7-5p/MyD88 regulation in cholangiocarcinoma adds a tumor-intrinsic route for restraining TGF-β-induced glycolysis and proliferation, but the atherosclerosis study broadens the cluster beyond cancer.
5 papers · 33.3%
-
MASH Fibrosis and Imaging
MASH fibrosis work is moving toward pairing pathway-directed treatment with noninvasive disease mapping. Indole-3-carbaldehyde, particularly in T2DM, is evaluated through SIRT1/TGF-β/SMAD effects on collagen, α-SMA and TIMP1. Integrin αvβ6 PET is being developed to visualize biliary and fibrotic remodeling before advanced pathology is evident. Whether these biomarkers and imaging endpoints predict antifibrotic benefit remains open.
2 papers · 13.3%
TGF-β is not uniformly pathogenic: in some settings, increasing or preserving its activity is therapeutic
In intestinal helminth infection and AMPK-deficient tolerogenic dendritic-cell models, TGF-β secretion was required for CD103+ dendritic cells to induce regulatory T cells, whereas in a murine full-thickness wound model, sustained local TGF-β release from iPRF–hyaluronic-acid microneedles accelerated closure, re-epithelialization, and collagen deposition 42748228Sep 42229655Jun. Against the set’s predominant use of TGF-β as a fibrotic or immunosuppressive pathway to inhibit, these independent systems show that TGF-β can instead support intestinal immune tolerance and tissue repair; therapeutic strategies therefore cannot treat its activation as intrinsically harmful.
TGF-β is identified as an upstream epigenetic regulator of antitumor cDC1 function through CARM1
In mouse and human cross-presenting dendritic cells exposed to tumor-immunity conditions, TGF-β regulated expression of the epigenetic enzyme CARM1, whose inactivation enhanced cDC1 antigen cross-presentation and T-cell priming 42424445Jul. This assigns TGF-β a role upstream of an epigenetic brake on cDC1 function, rather than solely as a downstream mediator of fibrosis, immune exclusion, or cellular suppression, creating a mechanistic direction in which interrupting TGF-β–CARM1 control could improve antitumor antigen presentation.
Papers
The 15 papers from the last 6 months that study Transforming growth factor beta (TGF-β) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Tissue Repair and Inflammation (8)
- Farnesol mitigates post-infarction ventricular remodeling via pharmacological modulation of the SPHK2/S1P/SMAD3 axis. European journal of pharmacology · 16 Sept 2026 PMID 42749007
- Metabolic sensor AMPK licenses intestinal CD103+ DCs to induce Treg responses. Science advances · 16 Sept 2026 PMID 42748228
- The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity. Science (New York, N.Y.) · 9 Jul 2026 PMID 42424445
- Dismantling the TGF-β Axis: A Critical Transition from Occupancy-based Kinase Inhibitors to Event-driven Degraders. Mini reviews in medicinal chemistry · 7 Jul 2026 PMID 42411223
- Paeoniae Decoction attenuates chronic colitis-associated intestinal fibrosis by suppressing TGF-β/Smad-mediated epithelial-mesenchymal transition and remodeling the metabolic microenvironment. Journal of ethnopharmacology · 24 Jun 2026 PMID 42341856
- Qishen Yiqi Dripping Pills Alleviate Myocardial Ischemia-Reperfusion-Induced Fibrotic Injury by Inhibiting Fibroblast Activation via the Transforming Growth Factor-Beta/Periostin Pathway. Journal of ethnopharmacology · 10 Jun 2026 PMID 42269799
- Photo-crosslinked methacrylated hyaluronic acid-iPRF hydrogel-based microneedles for accelerated wound repair. International journal of biological macromolecules · 2 Jun 2026 PMID 42229655
- Growth arrest of thoracic aortic aneurysms in aging Marfan mice. American journal of physiology. Heart and circulatory physiology · 1 Jun 2026 PMID 42222959
Cellular Plasticity and Immune Resistance (5)
- A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study. PloS one · 22 Sept 2026 PMID 42771603
- MiR-7-5p suppresses TGF-β-induced glycolysis and proliferation in intrahepatic cholangiocarcinoma by targeting MyD88. Human cell · 4 Jul 2026 PMID 42400723
- Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody. Journal for immunotherapy of cancer · 3 Jul 2026 PMID 42398968
- scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. PLoS computational biology · 26 Jun 2026 PMID 42361193
- Endothelial Cell Phenotypic Plasticity in Atherosclerosis. Handbook of experimental pharmacology · 18 Jun 2026 PMID 42313121
MASH Fibrosis and Imaging (2)
- Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway. Biochimica et biophysica acta. Molecular basis of disease · 11 Jul 2026 PMID 42435945
- Molecular PET imaging of integrin αvβ6 reveals biliary and fibrotic changes in preclinical MASH. Biomarker research · 10 Jul 2026 PMID 42426821
By study type
Observational studies and case reports (1)
- A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study. PloS one · 22 Sept 2026 PMID 42771603
Preclinical: animal, cell and lab studies (7)
- Metabolic sensor AMPK licenses intestinal CD103+ DCs to induce Treg responses. Science advances · 16 Sept 2026 PMID 42748228
- The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity. Science (New York, N.Y.) · 9 Jul 2026 PMID 42424445
- MiR-7-5p suppresses TGF-β-induced glycolysis and proliferation in intrahepatic cholangiocarcinoma by targeting MyD88. Human cell · 4 Jul 2026 PMID 42400723
- Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody. Journal for immunotherapy of cancer · 3 Jul 2026 PMID 42398968
- scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. PLoS computational biology · 26 Jun 2026 PMID 42361193
- Photo-crosslinked methacrylated hyaluronic acid-iPRF hydrogel-based microneedles for accelerated wound repair. International journal of biological macromolecules · 2 Jun 2026 PMID 42229655
- Growth arrest of thoracic aortic aneurysms in aging Marfan mice. American journal of physiology. Heart and circulatory physiology · 1 Jun 2026 PMID 42222959
Unclassified: not yet indexed with MeSH (7)
- Farnesol mitigates post-infarction ventricular remodeling via pharmacological modulation of the SPHK2/S1P/SMAD3 axis. European journal of pharmacology · 16 Sept 2026 PMID 42749007
- Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway. Biochimica et biophysica acta. Molecular basis of disease · 11 Jul 2026 PMID 42435945
- Molecular PET imaging of integrin αvβ6 reveals biliary and fibrotic changes in preclinical MASH. Biomarker research · 10 Jul 2026 PMID 42426821
- Dismantling the TGF-β Axis: A Critical Transition from Occupancy-based Kinase Inhibitors to Event-driven Degraders. Mini reviews in medicinal chemistry · 7 Jul 2026 PMID 42411223
- Paeoniae Decoction attenuates chronic colitis-associated intestinal fibrosis by suppressing TGF-β/Smad-mediated epithelial-mesenchymal transition and remodeling the metabolic microenvironment. Journal of ethnopharmacology · 24 Jun 2026 PMID 42341856
- Endothelial Cell Phenotypic Plasticity in Atherosclerosis. Handbook of experimental pharmacology · 18 Jun 2026 PMID 42313121
- Qishen Yiqi Dripping Pills Alleviate Myocardial Ischemia-Reperfusion-Induced Fibrotic Injury by Inhibiting Fibroblast Activation via the Transforming Growth Factor-Beta/Periostin Pathway. Journal of ethnopharmacology · 10 Jun 2026 PMID 42269799
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-24 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.